Characterization of occult hepatitis B infection among Iranian liver transplant recipients

Azam Khamseh1,2 | Vahdat Poortahmasebi1,3,4 | Saber Soltani1,2 | Mohsen Nasiritoosi5 | Ali Jafarian2 | Azam Ghaziasadi1,2 | Mehdi Norouzi1,2 | Saied Ghorbani1,6 | Narges Eslami3,4 | Seyed Mohammad Jazayeri1,2,6

1Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
2Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4Department of Bacteriology and Virology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
6Department of Virology, Iran University of Medical Sciences, Tehran, Iran

Correspondence
Seyed Mohammad Jazayeri, Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, PO Box: 15155-6446, Tehran, Iran.
Email: jazayerism@tums.ac.ir

Abstract

Background: The prevalence of occult hepatitis B infection (OBI) among Iranian liver transplant recipient patients has not been explored yet. The present study aimed to determine the OBI prevalence among Iranian liver transplant recipients.

Methods: This study encompassed 97 patients having undergone liver transplantation due to several clinical backgrounds in the Liver Transplantation Center, Tehran, Iran. After serological evaluation, two different types of PCR methods were applied for amplification of HBV DNA, followed by the direct sequencing of whole hepatitis B virus (HBV) surface genes.

Results: At the time of admission, none of the patients were positive for HBsAg. However, 24 (25%), 12 (12.3%), and 5 (5.1%) cases were positive for anti-HBc, hepatitis C virus (HCV), and hepatitis delta virus (HDV) antibodies, respectively. Moreover, two males were positive for OBI (2.1%). Both were positive for anti-HBc and negative for anti-HBs, anti-HCV, and anti-HDV. HBV-related cirrhosis was the underlying reason for their liver transplantation. HBsAg sequences revealed no amino acid substitution.

Conclusions: The prevalence of OBI in the Iranian liver transplantation patients was relatively low. Future longitudinal studies with a larger sample size are suggested to explore the significance of this clinical finding, including the reactivation of cryptic HBV DNA, in liver transplant subjects.

KEYWORDS
HBV reactivation, liver transplantation, occult HBV infection

1 | INTRODUCTION

Occult hepatitis B infection (OBI) refers to detecting HBV DNA in the absence of hepatitis B surface antigen (HbsAg). Due to its cryptic nature, OBI still retains the same pro-oncogenic features. It may contribute to the acute exacerbation and development of hepatitis B virus (HBV) associated diseases such as liver diseases, cirrhosis, and hepatocellular carcinoma (HCC).1,2 OBI has been described in various clinical settings,2 and one of the main clinical implications of OBI is usually observed in the setting of liver transplantation. In particular,
livers from donors with OBI carry a risk of HBV transmission, with infection arousing in 25%-95% of the liver grafts donated from patients being HbsAg-negative and anti-HBc-positive. This infection route cannot be distinguished from the chronic HbsAg-positive carrier state. The significance of OBI in post-orthotopic liver transplantation settings is controversial. Upon the analysis of intrahepatic HBV DNA, some patients show high liver or serum HBV DNA levels and a high reactivation rate, whereas some others have revealed low HBV reactivation rates. In this regard, the main goal is to maintain anti-HBs above the protection level (>10 IU/mL) in vaccine recipients. In 1993, the Iranian Ministry of Health launched an HBV vaccination program in all provinces, leading to the 98% coverage of all infants across the country. It is mandatory for neonates born after this time to be vaccinated using a recombinant HBsAg with classic three consecutive doses. According to recent statistics, Iran is classified as a low HBV prevalence area (<2%), indicating the effectiveness of the preventive measures in Iran. It is postulated that OBI can be found in most recipients of livers from HBsAg-negative and anti-HBc-positive donors. The likelihood of HBV reactivation would be minimized by immunization and preemptive treatment with nucleos(t)ide analog drugs as a standard strategy to prevent hepatitis B infection. Accordingly, liver transplant recipients currently receive pre-, during, and post-transplantation hepatitis B immune globulin (HBIG) with different options along with antivirals according to different global protocols. This study aimed to estimate the prevalence of HBsAg carriers and occult HBV infection among the Iranian liver transplant recipients.

2 MATERIALS AND METHODS

2.1 Patients

The present cross-sectional study encompassed 97 patients undergoing liver transplantation at the Liver Transplantation Center, Imam Khomeini Hospital, Tehran, during 2005-2018. They had the following clinical backgrounds as candidates for liver transplantation: cryptogenic cirrhosis (49, 50.6%), HBV-related cirrhosis (13, 13.4%), HCV-related cirrhosis (12, 12.4%), HBV/HCV-related cirrhosis (1, 1%), cirrhosis due to autoimmune hepatitis (17, 17.6%), fulminant hepatitis (1, 1%), Budd-Chiari (1, 1%), and primary sclerosing cholangitis (3, 3%). Most of the patients were transplanted during the last 3 years. Blood samples were collected during 2017-2018. The study was evaluated and approved by the Ethics Committee of the Tehran University of Medical Sciences. The patients’ history for the HBV vaccination before the transplantation time was unknown, and the authorities assumed that the transplant recipients had not received the HBV vaccine before transplantation. According to the routine guidelines in this center, all LT candidates received pegylated HBIG 10000 international unit (IU) intramuscularly immediately before transplantation, followed by 5000IU for the first seven postoperative days. Then, the patients received 1000IU for 4 weeks and then monthly to maintain 250IU. All HbsAg-positive patients also received Tenofovir (300mg daily) before transplantation and after transplantation as long as anti-HBs achieved 300IU. Finally, all transplant patients received daily Prograf (6 mg), Cellcept (2 mg), and Prednisolon (10 mg).

2.2 Serological assessments

The viral markers of HBV, including HBsAg, anti-HBs, anti-HBc, and anti-hepatitis delta virus (HDV; Diaper), were measured by the enzyme-linked immunosorbent assay according to the manufacturer’s protocol.

2.3 DNA extraction, polymerase chain reaction, and DNA sequencing

HBV DNA was extracted from 200μL of the aliquot of serum using the Qiagen Mini Blood Kit (Qiagen) according to the manufacturer’s instruction. Regardless of the serologic results, a quantitative real-time PCR was applied for all subjects using Fast-track diagnostics/SIEMENS kits (Luxembourg) following the manufacturer’s recommendations. The dynamic range of the assay claimed by the manufacturer was $10^2$-$10^9$ IU/mL [2-9 log$_{10}$] IU/mL, and the lower detection limit of the assay was 85IU/mL. Those samples negative in primary screening by real-time PCR were re-checked for OBI using another HBsAg gene-nested PCR approach, which was recommended by Taormina expert meeting on occult HBV infection. Subsequently, a nested PCR was carried out for positive cases, as described previously.

The nucleotide sequences of the HBsAg encoding component were determined bilaterally by the 3130 Genetic Analyzer (Genetic Analyzer ABI-3130 DNA Sequencer). The sequences were compared, and edited, and the extra sections were deleted with Chromas software. Finally, the sequences encompassing the 681 nucleotides of the gene encoding HBsAg were transferred to BioEdit software version 7.0.9 in FASTA format. Seven HBV genotype D-matched sequences (namely CQ183486, AY161150, AB0335591, AF061523.1, X80925, X65259, and X65259 were obtained from the NCBI site) to study the mutations in the HBsAg region. Genotyping was performed by the phylogenetic analyses for the reference sequences of the HBV genotypes A-H. A maximum likelihood (ML) tree was created using the alignment of the HBsAg gene of the subjects by rooting with a Woodchuck hepatitis virus. The phylogenetic tree was generated with MEGA X software, and the genetic distance was calculated using Kimura’s two-parameter matrix. Bootstrap resampling and reconstruction were carried out 1000 times to confirm the reliability of the phylogenetic tree.

2.4 Statistical analysis

Data were analyzed with the Statistical Package for the Social Sciences (SPSS-21, SPSS Inc.). The continuous variables were
TABLE 1 General characteristics of patients with history of liver disease

| Patient Code | Age | Date Link | Date Link | Real time | HBs Ag | HBs Ab | HBe Ag and HBe Ab | HCV Ab | HDV Ab | Etiology                   |
|--------------|-----|-----------|-----------|-----------|--------|--------|-------------------|--------|--------|---------------------------|
| 1            | 55  | 1394      | 2015      | -         | 3.99   | Positive| Positive          | HCV cirrhosis |
| 2            | 60  | 1393      | 2014      | -         | 82     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 3            | 27  | 1394      | 2015      | -         | 251    | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 4            | 29  | 1394      | 2015      | -         | 0      | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 5            | 15  | 1394      | 2015      | -         | 263    | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 6            | 33  | 1394      | 2015      | -         | 0      | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 7            | 56  | 1394      | 2015      | -         | 0.99   | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 8            | 45  | 1392      | 2013      | Positive  | 0      | Positive| -                 | -       | -     | HBV cirrhosis              |
| 9            | 52  | 1392      | 2013      | -         | 1.2    | Positive| -                 | -       | -     | Hepatitis C - Hepatitis B |
| 10           | 52  | 1394      | 2015      | -         | 252    | Positive| Positive          | -       | -     | HCV cirrhosis              |
| 11           | 62  | 1394      | 2015      | -         | 0.11   | Positive| -                 | -       | -     | Cryptogenic cirrhosis      |
| 12           | 54  | 1393      | 2014      | -         | 0      | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 13           | 41  | 1393      | 2014      | -         | 0      | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 14           | 24  | 1394      | 2015      | -         | 274    | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 15           | 59  | 1392      | 2013      | -         | 68     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 16           | 37  | 1384      | 2005      | -         | 0      | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 17           | 25  | 1389      | 2010      | -         | 301    | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 18           | 23  | 1389      | 2010      | -         | 10     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 19           | 47  | 1389      | 2010      | -         | 0      | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 20           | 46  | 1393      | 2014      | -         | 283    | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 21           | 40  | 1394      | 2015      | -         | 0      | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 22           | 35  | 1391      | 2012      | -         | 67     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 23           | 32  | 1392      | 2013      | -         | 23     | -       | -                 | -       | -     | Budd-Chiari cirrhosis      |
| 24           | 62  | 1394      | 2015      | -         | 305    | Positive| -                 | -       | -     | Cryptogenic cirrhosis      |
| 25           | 37  | 1393      | 2014      | -         | 0      | -       | -                 | -       | -     | Primary sclerosing cholangitis, cirrhosis |
| 26           | 50  | 1394      | 2015      | -         | 0      | Positive| -                 | HCV cirrhosis |
| 27           | 57  | 1394      | 2015      | -         | 48     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 28           | 65  | 1394      | 2015      | -         | 280    | Positive| -                 | HCV cirrhosis |
| 29           | 50  | 1391      | 2012      | -         | 0      | Positive| -                 | -       | -     | HBV cirrhosis              |
| 30           | 38  | 1393      | 2014      | -         | 0      | Positive| -                 | HCV cirrhosis |
| 31           | 46  | 1391      | 2012      | -         | 20     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 32           | 63  | 1393      | 2014      | -         | 19     | Positive| -                 | -       | -     | HBV cirrhosis              |
| 33           | 30  | 1391      | 2012      | -         | 17     | -       | -                 | -       | -     | Autoimmune Hepatitis-cirrhosis |
| 34           | 21  | 1393      | 2014      | -         | 17     | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 35           | 35  | 1386      | 2007      | -         | 0      | -       | -                 | -       | -     | Cryptogenic cirrhosis      |
| 36           | 48  | 1391      | 2012      | -         | 0      | -       | -                 | -       | -     | Cryptogenic cirrhosis      |

(Continues)
| Patient Code | Age | Date Link | Date Link | Real time | HBs Ag | HBs Ab | HBe Ag and HBe Ab | HCV Ab | HDV Ab | Etiology |
|--------------|-----|-----------|-----------|-----------|--------|--------|-------------------|--------|--------|----------|
| 37           | 44  | 1392      | 2013      | Positive  | 0      | Positive | -                 | -      | -      | HBV cirrhosis |
| 38           | 21  | 1392      | 2013      | -         | 1.2    | -       | -                 | -      | -      | Autoimmune Hepatitis- cirrhosis |
| 39           | 1391| 2012      | -         | -         | 1.6    | -       | -                 | -      | -      | Autoimmune Hepatitis- cirrhosis |
| 40           | 50  | 1394      | 2015      | -         | 104    | Positive | -                 | -      | -      | Cryptogenic cirrhosis |
| 41           | 53  | 1394      | 2015      | -         | 53     | Positive | -                 | -      | -      | HCV cirrhosis |
| 42           | 1394| 2015      | -         | -         | 79     | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 43           | 52  | 1392      | 2013      | -         | 0.17   | Positive | -                 | -      | Positive | Cryptogenic cirrhosis |
| 44           | 60  | 1389      | 2010      | -         | 0      | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 45           | 63  | 1391      | 2012      | -         | 3.8    | Positive | -                 | -      | Positive | HBV cirrhosis |
| 46           | 52  | 1395      | 2016      | -         | 32     | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 47           | 50  | 1394      | 2015      | -         | 25     | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 48           | 46  | 1394      | 2015      | -         | 12     | -       | -                 | -      | Positive | HCV cirrhosis |
| 49           | 43  | 1394      | 2015      | -         | 0.84   | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 50           | 26  | 1394      | 2015      | -         | 73     | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 51           | 42  | 1393      | 2014      | -         | 1.3    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 52           | 63  | 1395      | 2016      | -         | 3.7    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 53           | 27  | 1394      | 2015      | -         | 126    | -       | -                 | -      | -      | Primary sclerosing cholangitis, cirrhosis |
| 54           | 24  | 1385      | 2006      | -         | 254    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 55           | 55  | 1389      | 2010      | -         | 0.5    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 56           | 63  | 1392      | 2013      | -         | 0.2    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 57           | 25  | 1391      | 2012      | -         | 6      | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 58           | 60  | 1394      | 2015      | -         | 11     | Positive | -                 | -      | -      | Cryptogenic cirrhosis |
| 59           | 46  | 1392      | 2013      | -         | 4/0    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 60           | 38  | 1391      | 2012      | -         | 17/3   | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 61           | 31  | 1390      | 2011      | -         | 19     | -       | -                 | -      | -      | Autoimmune Hepatitis- cirrhosis |
| 62           | 55  | 1393      | 2014      | -         | 9/2    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 63           | 1394| 2015      | -         | -         | 135    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 64           | 53  | 1395      | 2016      | -         | 258    | Positive | -                 | -      | -      | HBV cirrhosis |
| 65           | 1387| 2008      | -         | -         | 4      | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 66           | 1394| 2015      | -         | -         | 4      | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 67           | 40  | 1394      | 2015      | -         | 13     | -       | -                 | -      | -      | Autoimmune Hepatitis- cirrhosis |
| 68           | 42  | 1391      | 2012      | -         | 5/3    | Positive | -                 | -      | -      | HBV cirrhosis |
| 69           | 1388| 2009      | -         | -         | 4/2    | -       | Positive | -       | -      | HCV cirrhosis |
| 70           | 1392| 2013      | -         | -         | 34     | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 71           | 1389| 2010      | -         | -         | 7/0    | Positive | -                 | -      | -      | HBV cirrhosis |
| 72           | 24  | 1391      | 2012      | -         | 211    | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 73           | 1395| 2016      | -         | -         | 1      | -       | -                 | -      | -      | Cryptogenic cirrhosis |
| 74           | 1394| 2015      | -         | -         | 9/0    | Positive | -                 | -      | -      | HCV cirrhosis |
| 75           | 60  | 1393      | 2014      | -         | 273    | Positive | -                 | -      | -      | Cryptogenic cirrhosis |
| 76           | -   | -         | -         | -         | 13     | Positive | -                 | -      | -      | Cryptogenic cirrhosis |
| 77           | 55  | 1393      | 2014      | -         | 7/6    | -       | -                 | -      | -      | Autoimmune Hepatitis- cirrhosis |
expressed as mean ± standard deviation or median, and the categorical variables were expressed as percentages.

3 | RESULTS

Of the 97 patients, 57 (58%) and 40 (42%) individuals were male and female, respectively. The participants' age ranged from 15 to 65 years old, with the mean age of 47.66 ± 11.71 for males and 38.72 ± 13.07 for females (P = .002). At the time of presentation, no case was positive for HBsAg; however, 24 (25%), 12 (12.3%), and 5 (5.1%) cases were positive for anti-HBc, anti-HCV, and anti-HDV, respectively (Table 1). Moreover, 21 (27%) and 3 (7.5%) males and females were positive for anti-HBc, respectively. Of the anti-HCV-positive cases, 9 (15.7%) and 3 (7.5%) individuals were male and female, respectively. Finally, 4 (7%) and 1 (2.5%) cases of the HDV-positive patients were male and female, respectively. Two 44 and 45-year-old males were positive for OBI (2.1%), both of whom were diagnosed by the real-time and standard PCR methods. Both OBI-positive samples contained HBV DNA levels <500 copies/mL. The OBI diagnosis was reached 2 years after transplantation. Both cases were positive for anti-HBc and negative for anti-HBs, anti-HCV, and anti-HDV. Furthermore, HBV-related cirrhosis was the underlying reason for their liver
**FIGURE 1** Maximum likelihood phylogenetic tree construction based on the Clustal W alignment of two HBsAg sequences (681-bp) obtained from Iranian liver transplant patients.

**FIGURE 2** Details of two HBsAg sequences from OBI-positive cases. Seven HBV genotype D-matched sequences (namely CQ183486, AY161150, AB0335591, AF061523.1, X80925, X65259, and X65259) were obtained from the NCBI site to evaluate mutations in the HBsAg region. Amino acid substitutions are shown in different colors by the BioEdit program. Seven top sequences belonged to the HBsAg sequences from a genotype D-matched isolate.
transplantation. The phylogenetic tree results revealed that both isolates were HBV genotype D and subtype ayw2 (Figure 1). In comparison to seven HBV genotype D sequences, the HBsAg gene and also “a” determinant region (amino acid positions 124-147) revealed no amino acid substitution (Figure 2). Both sequences have been submitted to the GenBank under accession numbers: MT003226-MT003227. During the follow-up period (started in 2005), none of the patients, including the OBI-positive cases, developed the evidence of HBV reactivation.

4 | DISCUSSION

One of the main clinical implications of OBI is usually observed in the setting of liver transplantation. In particular, livers from donors with OBI carry a risk of HBV transmission, with infection arising in 25%-95% of the liver grafts donated from patients being HBsAg negative and anti-HBc positive. The present study documented the relatively low prevalence of OBI among the Iranian liver transplant recipients (2.1%). OBI is one of the causes of cryptogenic cirrhosis, and there is 38% OBI among Iranian patients diagnosed with this type of clinical setting. Another Iranian study reported 14% OBI in this clinical setting. However, using two different sensitive molecular approaches, we found no symptom of HBV DNA in 49 patients diagnosed with cryptogenic cirrhosis before LT. It is suggested that no cccDNA exists after LT and the resection of the liver with the lack of the primary source for HBV replication. However, cccDNA could have existed in other extrahepatic sources such as PBMC.

Two OBI patients in the present study were positive for anti-HBc and negative for anti-HBs. The hypothesis behind the low prevalence of OBI among Iranian liver transplant recipients remains elusive. However, several factors have been attributed to the evolution of HBV around the globe, of which the HBV genetic variations with the highest frequency have been the most underlying factor. Several HBV mutations within the “a” determinant of HBsAg have been reported in association with OBI. However, in the present study, no mutation was found in this regard in any patient. According to the findings released by the Iran Hepatitis Network, all Iranian HBV-positive carriers contained genotype D, and 61.9% of the Iranian chronic HBV carriers had mutations in their HBsAg genes. However, of 542 amino acid variations, 404 (74.5%) cases were naturally occurring mutations. This unique pattern has not been reported for other HBV-infected populations yet.

On the other hand, the HBV genotypes B and C are prevalent among Southeast Asian chronic HBV populations. Those genotypes contained the highest heterogeneity, including sub-genotypes (inter-host variations) and mutational drifts (intra-host variations). Nevertheless, the HLA-related genetic background of these populations contributed to a high HBV chronicity rate and the relevant consequences of the HBV infection, including cirrhosis and HCC.

5 | CONCLUSIONS

The prevalence of OBI among Iranian patients referred to one of the two Iranian referral centers for liver transplantation was relatively low. Future longitudinal studies are required to employ a larger sample size to explore the significance of this clinical finding, including the reactivation of cryptic HBV DNA, in liver transplant subjects.

AUTHOR CONTRIBUTIONS

Study concept, design, and drafting of the manuscript: Seyed Mohammad Jazayeri and Mohsen Nasiri toosi; Acquisition of data and experimental analysis: Azam Khamseh, Vahdat Poortahmasebi, Azam Ghaziasadi, Saber Soltani, and Saeid Ghorbani; Interpretation of data: Ali Jafarian, Mehdi Norouzi and Narges Eslami.

ACKNOWLEDGMENTS

The authors would like to thank the Iranian Research Center for Clinical Virology and the Liver Transplantation Research Center for their cooperation in the study.

CONFLICT OF INTEREST

None of the authors declared any conflict of interest.

DATA AVAILABILITY STATEMENT

All data related to this work are available from the corresponding author upon reasonable request.

ORCID

Vahdat Poortahmasebi https://orcid.org/0000-0001-5409-2121
Saber Soltani https://orcid.org/0000-0003-3369-0856

REFERENCES

1. Pollicino T, Squadríto G, Cerenza G, et al. Hepatitis B virus maintains its pro- oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102-110.
2. Alavian SM, Mīrī SM, Hollinger FB, Jazayeri SM. Occult Hepatitis B (OBH) in clinical settings. Hepat Mon. 2012;12(8):e6126.
3. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl. 2007;13(8):1137-1144.
4. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology. 2003;38(1):86-95.
5. Ghisettì V, Marzano A, Zamboni F, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl. 2004;10(3):356-362.
6. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14(4):534-540.
7. Ciesek S, Helfritz FA, Lehmann U, et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis. 2008;197(3):355-360.
8. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B virus infection in the general population of
Iran: an updated systematic review and meta-analysis. Hepat Mon. 2016;16(4):e35577.

9. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152-162.

10. Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Monthly. 2012;12(3):168-176.

11. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652-657.

12. Ghaziasadi A, Alavian SM, Norouzi M, Fazeli Z, Jazayeri SM. Mutational analysis of HBs Ag-positive mothers and their infected children despite immunoprophylaxis. Iran J Allergy Asthma Immunol. 2013;12(4):352-360.

13. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16(2):111-120.

14. Efron B, Halloran E, Holmes S. Bootstrap confidence levels for phylogenetic trees. Proc Natl Acad Sci USA. 1996;93(23):13429-13434.

15. Anvari FA, Alavian SM, Norouzi M, Mahabadi M, Jazayeri SM. Prevalence and molecular analysis of occult hepatitis B virus infection isolated in a sample of cryptogenic cirrhosis patients in Iran. Oman Med J. 2014;29(2):92-96.

16. Hashemi SJ, Hajiani E, Masjedizadeh A, et al. Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of Iran. Jundishapur J Microbiol. 2015;8(3):e16873.

17. Vicenti I, Rossetti B, Mariano S, et al. Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia. New Microbiol. 2018;41(4):302-305.

18. Alavian SM, Carman WF, Jazayeri SM. HBsAg variants: diagnostic-escape and diagnostic dilemma. J Clin Virol. 2013;57(3):201-208.

19. Khedive A, Norouzi M, Ramezani F, et al. Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study. J Viral Hepat. 2013;20(7):494-501.

20. Utsumi U, Yano Y, Hotta H. Molecular epidemiology of hepatitis B virus in Asia. World J Med Genet. 2014;4(2):19-26.

21. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57(3-4):141-150.

22. Wang L, Zou ZQ, Wang K. Clinical relevance of HLA gene variants in HBV infection. J Immunol Res. 2016;2016:9069375.

23. Fan J, Huang X, Chen J, et al. Host genetic variants in HLA loci influence risk for hepatitis B virus infection in children. Hepat Mon. 2016;16(8):e37786.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Khamseh A, Poortahmasebi V, Soltani S, et al. Characterization of occult hepatitis B infection among Iranian liver transplant recipients. J Clin Lab Anal. 2022;36:e24614. doi: 10.1002/jcla.24614